Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Inflammatory Bowel Disease II: Ulcerative Colitis

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease II: Pathophysiology

Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Optimizing recruitment in rare disease research: a cross-sectional online study evaluating sampling strategies for hard-to-reach populations.

Orphanet journal of rare diseases·2026

Same author

<sup>68</sup>Ga-FAPI PET/CT for non-invasive characterization and activity assessment of ulcerative colitis and Crohn´s disease.

European journal of nuclear medicine and molecular imaging·2026

Same author

Haplotype-based autoencoders can reduce the dataset dimension and estimate haplotype block effects in different crop species.

BMC bioinformatics·2025

Same author

The role of copper dysregulation in Wilson disease: an expert opinion.

Frontiers in medicine·2025

Same author

Diabetes-preventive molecular mechanisms of breast versus formula feeding: new insights into the impact of milk on stem cell Wnt signaling.

Frontiers in nutrition·2025

Same author

Peer Support in Chronic Conditions from the Peer Supporters' Perspective: A Systematic Review.

Psychosocial intervention·2025

Search research articles

Related Experiment Videos

Delayed release phosphatidylcholine in chronic-active ulcerative colitis: a randomized, double-blinded, dose finding

Wolfgang Stremmel¹, Annika Braun, Anja Hanemann

¹Department of Gastroenterology, University Hospital Heidelberg, Heidelberg, Germany. wolfgang_stremmel@med.uni-heidelberg.de

Journal of Clinical Gastroenterology

|January 6, 2010

Summary

Delayed release phosphatidylcholine (rPC) at doses of 1g or higher effectively treats chronic-active ulcerative colitis. Higher doses of 3g and 4g rPC appear superior for achieving remission.

Related Experiment Videos

Area of Science:

Gastroenterology
Pharmacology
Clinical Therapeutics

Background:

Previous studies indicated delayed release phosphatidylcholine (rPC) improves disease activity and facilitates steroid withdrawal in ulcerative colitis.
Chronic-active ulcerative colitis presents a therapeutic challenge requiring effective treatment strategies.

Purpose of the Study:

To determine the optimal dosage of oral rPC for treating chronic-active ulcerative colitis.
To identify the rPC dose associated with the fewest adverse events.

Main Methods:

A randomized, dose-controlled, double-blind study involving 40 patients with chronic-active ulcerative pancolitis.
Patients received oral rPC at doses of 0.5g, 1g, 3g, or 4g daily for 12 weeks.
Disease activity was assessed using the Clinical Activity Index (CAI) and Endoscopic Activity Index (EAI).

Main Results:

Significant improvement in CAI was observed with rPC doses of 1g, 3g, and 4g compared to the 0.5g control dose (P<0.05).
Remission (CAI ≤3) was achieved in 50% (3g group) and 60% (4g group) of patients, versus none in the 0.5g group.
Clinical response rates (≥50% CAI improvement) reached 70% across effective dose groups (1-4g), paralleled by endoscopic healing.

Conclusions:

A saturable dose-response relationship for rPC in ulcerative colitis treatment was identified, with effective doses starting at 1g daily.
Doses of 3g and 4g of rPC demonstrated superior efficacy in inducing remission compared to lower doses.